| P50 | author | John C O'Horo | Q54233949 |
| | Kazuaki Jindai | Q56948053 |
| P2093 | author name string | N Safdar | |
| | B Kunzer | |
| P2860 | cites work | Fecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality | Q84305336 |
| | Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea | Q84598282 |
| | Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis | Q93627416 |
| | Enterotypes of the human gut microbiome | Q24489818 |
| | Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis | Q24529831 |
| | The gut flora as a forgotten organ | Q24550824 |
| | Treating Clostridium difficile infection with fecal microbiota transplantation | Q24634294 |
| | The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 |
| | Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope | Q28138671 |
| | Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis | Q28184074 |
| | A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease | Q28254686 |
| | Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results | Q28255085 |
| | Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection | Q28258490 |
| | Clostridium difficile-associated diarrhea treated with homologous feces | Q28266807 |
| | Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea | Q28269350 |
| | Duodenal infusion of donor feces for recurrent Clostridium difficile | Q28283517 |
| | Nitazoxanide for the treatment of Clostridium difficile colitis | Q33250018 |
| | Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide | Q33276804 |
| | A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial | Q33393311 |
| | Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study | Q33398747 |
| | Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube | Q33964412 |
| | Success of self-administered home fecal transplantation for chronic Clostridium difficile infection | Q34021088 |
| | Treatment with monoclonal antibodies against Clostridium difficile toxins | Q34093904 |
| | Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). | Q34105840 |
| | Fidaxomicin versus vancomycin for Clostridium difficile infection | Q34162172 |
| | Comparative effectiveness of Clostridium difficile treatments: a systematic review | Q34241798 |
| | Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial | Q34409185 |
| | An epidemic, toxin gene-variant strain of Clostridium difficile | Q34472146 |
| | Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series | Q34611463 |
| | Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol | Q34620553 |
| | Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection | Q34633079 |
| | Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection | Q34634195 |
| | Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population | Q34786314 |
| | Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin | Q34880915 |
| | Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes | Q34977849 |
| | Intravenous immunoglobulin therapy for severe Clostridium difficile colitis | Q35841034 |
| | Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. | Q36071504 |
| | Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin | Q36071524 |
| | Treatment of Clostridium difficile-associated disease: old therapies and new strategies | Q36240849 |
| | Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea | Q36416873 |
| | Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties | Q36700782 |
| | Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance | Q36948257 |
| | The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review | Q37382913 |
| | The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy | Q37584456 |
| | Economic healthcare costs of Clostridium difficile infection: a systematic review | Q37691876 |
| | Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options | Q37963691 |
| | Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection | Q37966763 |
| | Strategies for prevention of Clostridium difficile infection | Q37992599 |
| | Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis | Q38030871 |
| | A prospective cohort study on hospital mortality due to Clostridium difficile infection | Q39587051 |
| | Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients | Q40291508 |
| | Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis | Q40445495 |
| | Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. | Q40595223 |
| | Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection | Q42163253 |
| | Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series | Q42949674 |
| | Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea | Q43006167 |
| | Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? | Q43257958 |
| | Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment | Q43288011 |
| | Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin | Q43627285 |
| | Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients | Q43678916 |
| | Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease | Q44074819 |
| | Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii | Q44084557 |
| | Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii | Q44136249 |
| | Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial | Q44222933 |
| | PRISMA statement | Q44518422 |
| | Vital signs: preventing Clostridium difficile infections. | Q44610964 |
| | Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea | Q44836632 |
| | Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada | Q46486664 |
| | Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology | Q46490780 |
| | Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study | Q46666949 |
| | Intravenous immunoglobulin for resistant Clostridium difficile infection | Q46816696 |
| | Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea | Q46843245 |
| | Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada | Q46943788 |
| | Emergence of reduced susceptibility to metronidazole in Clostridium difficile | Q47664069 |
| | Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection | Q47979492 |
| | Quality Assurance: Potential Use for the Newly Described Exposure Index in Clinical Practice | Q53062691 |
| | Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. | Q53751419 |
| | Putting back the bugs: bacterial treatment relieves chronic diarrhoea. | Q55066115 |
| | Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe | Q58924160 |
| | Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin | Q59567863 |
| | Clostridium difficile-Associated Diarrhea and Colitis | Q60362148 |
| | Association of Interleukin-8 Polymorphism and Immunoglobulin G Anti–Toxin A in Patients With Clostridium difficile–Associated Diarrhea | Q61833618 |
| | Clindamycin-associated colitis. A prospective study | Q68788475 |
| | Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain | Q68988457 |
| | Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients | Q69370183 |
| | Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG | Q69911178 |
| | [Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis] | Q70172889 |
| | Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis | Q71304055 |
| | Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces | Q71408119 |
| | Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG | Q71512642 |
| | The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii | Q73118857 |
| | Reccurent pseudomembranous colitis treated with the donor feces | Q73268296 |
| | [Feces culture successful therapy in Clostridium difficile diarrhea] | Q79415353 |
| | Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea | Q79895613 |
| | [First experiences with faecal bacteriotherapy in the treatment of relapsing pseudomembranous colitis due to Clostridium difficile] | Q83248493 |
| | Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection--results and follow-up | Q84186073 |
| | Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients | Q84210629 |
| P433 | issue | 1 | |
| P921 | main subject | Clostridium difficile | Q310543 |
| | systematic review | Q1504425 |
| P304 | page(s) | 43-59 | |
| P577 | publication date | 2013-07-10 | |
| P1433 | published in | Infection | Q15710156 |
| P1476 | title | Treatment of recurrent Clostridium difficile infection: a systematic review | |
| P478 | volume | 42 | |